Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review

Fineline Cube Sep 28, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration...

Company Drug

Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009

Fineline Cube Sep 28, 2023

Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...

Company Deals

Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline

Fineline Cube Sep 28, 2023

China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured...

Company Drug

Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH

Fineline Cube Sep 28, 2023

Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47

Fineline Cube Sep 28, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...

Company Deals

MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices

Fineline Cube Sep 28, 2023

MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD...

Company Drug

Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821

Fineline Cube Sep 28, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...

Company Drug

LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China

Fineline Cube Sep 28, 2023

Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...

Policy / Regulatory

Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...

Policy / Regulatory

Beijing-Tianjin-Hebei Region Initiates Drug VBP with 37 Medicines, Including Biologics

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has issued a notification to commence the drug volume-based...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics to Advance Hearing Loss Treatments

Fineline Cube Sep 27, 2023

Regeneron Pharmaceuticals (NASDAQ: REGN) has completed the acquisition of Decibel Therapeutics, a developer of gene...

Company Deals

Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies

Fineline Cube Sep 27, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company...

Company Drug

Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast

Fineline Cube Sep 27, 2023

Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the...

Company Drug

Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment

Fineline Cube Sep 27, 2023

Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of...

Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment

Fineline Cube Sep 27, 2023

United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...

Company Drug

BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02

Fineline Cube Sep 27, 2023

BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...

Company Drug

Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China

Fineline Cube Sep 27, 2023

The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...

Company

Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs

Fineline Cube Sep 27, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report...

Company Deals

Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership

Fineline Cube Sep 27, 2023

Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application...

Company

Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus

Fineline Cube Sep 27, 2023

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first...

Posts pagination

1 … 519 520 521 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.